penpulimab   Click here for help

GtoPdb Ligand ID: 12347

Synonyms: AK-105 | AK105
Approved drug Immunopharmacology Ligand
penpulimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Penpulimab (AK-105) is a chimeric IgG1κ programmed cell death 1 (PD-1) monoclonal antibody [2]. Its engineered Fc structure means that it does not interact with Fcγ receptors and therefore it does not induce immune cell (macrophage) effector functions (antibody-dependent cell-mediated cytotoxicity/ADCC, antibody-dependent cellular phagocytosis/ADCP, antibody-dependent cytokine release/ADCR). Penpulimab binds to an epitope in human PD-1's N-glycosylation site (at residue N58).
Click here for help
No information available.
Summary of Clinical Use Click here for help
Penpulimab was granted its first clinical approval in China (August 2021) [1]. It was indicated to treat nasopharyngeal cancer and NSCLC at that time.